Lipid-lowering therapy in selected specific groups of patients

Pavel Kraml

doi:10.36290/med.2020.029

June 18, 2020Medicína pro praxiOpen Access

Lipid-lowering therapy in selected specific groups of patients

View Full Paper

Ask AI

Bookmark

Share

Structured PICO

P

Population

Patients with secondary hyperlipoproteinemias (dyslipidemias) associated with chronic kidney disease (CKD), liver disease (NAFLD, alcoholic liver disease, cirrhosis, post-transplant), and autoimmune rheumatic diseases (rheumatoid arthritis, SLE, antiphospholipid syndrome, systemic sclerosis).

I

Intervention

Lipid-lowering therapy

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This review summarizes the pathophysiology and management of secondary dyslipidemias in patients with chronic kidney disease, liver disease, and autoimmune rheumatic diseases.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pavel Kraml (2020) studied this question.

synapsesocial.com/papers/6a72468fe36a167817e3c307 https://doi.org/10.36290/med.2020.029

View Full Paper

Ask AI

Bookmark

Share

Lipid-lowering therapy in selected specific groups of patients

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Lipid-lowering therapy in selected specific groups of patients

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading